Enzo Biochem Inc. (ENZ)

The role of biotechnology in diagnostics
1. Presymptomatic testing for estimating the risk of developing adult-onset cancers: Persons with a mutation in the BRCA1 gene has a 65% cumulative chance of developing breast cancer
2. Confirmational diagnosis of symptomatic individuals: for example cystic fibrosis and Huntington's disease
3. Forensic/identity testing: for example analysis of semen for prosecution of sexual offenders, analysis of blood, bone and hair of murder victims, paternity testing.

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. Since ENZ was founded in 1976, their strategic focus has been on the development of enabling technologies in the life sciences field.

Enzo Biochem Inc. recently announced that it has added four highly experienced executives at its Enzo Life Sciences subsidiary to focus on rapidly evolving new pharmaceutical and clinical applications.

The officers, all filling newly created positions, are Bruce Taillon, PhD, as head of global technology business development, John D'Errico, PhD, to lead the commercial merchandising operations, Kara Cannon, as head of global marketing and Paul Munger, PhD, to lead Global Manufacturing.

Over the past two years, Enzo has been engaged in enhancing the Life Sciences subsidiary's operating performance through added capabilities, greater integration and a more focused product mix. These efforts are all aimed at significantly expanding Enzo's presence and marketing beyond the traditional academic and research laboratory core to greater penetrate the pharmaceutical and clinical customer base with new and cutting edge platform technologies.

For more information please visit: www.enzo.com

****************************


Cleantech Transit, Inc. (CLNO)
Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company's ability to earn in 25% of the 500KW Merced Project.

The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.

Biomass is a completely renewable resource. Fuel can be produced using grains and plant waste that would otherwise go unused. Many of these plants and grains can be replaced the very next growing season.

Organic waste in the form of dead trees, leaves, grass clippings, animal carcasses and byproducts from food processing exists in abundance and can be used to produce biomass energy. This means that a large amount of solid waste that is currently just dumped into landfills can be used as a source of energy.

Waste products generated by human activity, such as paper and household garbage can be collected and used as biomass to generate energy. This could have the effect of reducing the amount of waste generated and sent to landfills or placed on barges and sent out to sea by millions of tons a year.







Read the full article and the disclaimer atennyotcstock.com/?p=17404